Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Total Non-Current Liabilities (2017 - 2025)

Pharma-Bio Serv (PBSV) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Jul 2025, changed N/A, and an annual FY2024 reading of $1.9 million, changed N/A over the prior year.
  • Total Non-Current Liabilities was $1.7 million for Q3 2025 at Pharma-Bio Serv, down from $1.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $8.9 million in Q1 2021 and bottomed at $1.7 million in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $3.9 million, with a median of $4.2 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities soared 77.42% in 2021, then crashed 50.81% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $5.0 million in 2021, then plummeted by 50.81% to $2.5 million in 2022, then rose by 9.34% to $2.7 million in 2023, then dropped by 28.6% to $1.9 million in 2024, then fell by 13.42% to $1.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for PBSV at $1.7 million in Q3 2025, $1.8 million in Q2 2025, and $1.9 million in Q4 2024.